Prosecution Insights
Last updated: October 01, 2026

Examiner: RESTAINO, ANDREW PETER

Tech Center 3700 • Art Units: 3771 3796

This examiner grants 72% of resolved cases

Analysis

Andrew Peter Restaino, operating in Tech Center 3700 and Art Unit 3771, has a record of 284 resolved cases. His allowance rate of 72.5% indicates a generally receptive approach to patent applications. This metric suggests that a majority of the cases he resolves result in an allowance, providing a positive outlook for applicants during the initial stages of prosecution.

The median days to allowance is 1027, which serves as a standard measure of the time required to reach a grant. A notable feature of his data is the interview lift of 39.5%. This figure shows that the probability of success increases significantly when practitioners engage in an interview, offering a clear path to improve upon the 72.5% baseline allowance rate.

With 284 resolved cases, the examiner's 39.5% interview lift is a statistically relevant factor for strategy development. The 1027-day median duration can be managed more effectively by utilizing the lift associated with direct communication. Applicants should prioritize interviews to navigate Art Unit 3771, as the data suggests this examiner is open to resolving issues through verbal discussion.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

72.5%
Allow Rate
+2.5% vs TC avg
332
Total Applications
+39.5%
Interview Lift
1027
Avg Prosecution Days
Based on 284 resolved cases, 2023–2026

Rejection Statute Breakdown

0.8%
§101 Eligibility
24.4%
§102 Novelty
45.7%
§103 Obviousness
25.1%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18931673 ELECTRICALLY ENHANCED RETRIEVAL OF MATERIAL FROM VESSEL LUMENS Non-Final OA Covidien LP
18987281 GAP SEALING SYSTEM AND KIT Final Rejection BOSTON SCIENTIFIC SCIMED, INC.
18930183 DELIVERY DEVICE FOR OCCLUSIVE IMPLANTS Non-Final OA Boston Scientific Scimed, Inc.
18596039 Technique For Determining A Patient-Specific Marker Arrangement For A Tracker Of A Surgical Tracking System Non-Final OA Stryker European Operations Limited
18983454 Left Atrial Appendage Occluder Devices Non-Final OA St. Jude Medical, Cardiology Division, Inc.
19192595 GAP COVERING EXPANDABLE IMPLANT FOR PREVENTING BLOOD LEAKAGE BETWEEN THERAPEUTIC DEVICE AND TISSUE AND ASSOCIATED DEVICES, SYSTEMS, AND METHODS Non-Final OA KONINKLIJKE PHILIPS N.V.
18654479 System For Effecting And Controlling Oscillatory Pressure Within Balloon Catheters For Fatigue Fracture Of Calculi Final Rejection The Regents of The University of Michigan
18939349 MAGNETIC MILLI-SPINNER FOR UNTETHERED ROBOTIC ENDOVASCULAR SURGERY AND METHODS FOR USE Non-Final OA The Board of Trustees of the Leland Stanford Junior University
19240362 BI-MODAL ULTRASONIC HANDPIECE SYSTEM Non-Final OA Alcon Inc.
18940504 PERICARDICAL TRANSECTION DEVICES AND METHOD Final Rejection EDWARDS LIFESCIENCES CORPORATION
18097365 EXPANDABLE INTRODUCER FOR DILATING THE DISTAL TIP OF AN INTRODUCER SHEATH Final Rejection Edwards Lifesciences Corporation
17812669 SYSTEMS AND METHODS FOR FLUID CONTROL Final Rejection Edwards Lifesciences Corporation
18089412 IRRIGATION DAMPING IN PHACOEMULSIFICATION Final Rejection JOHNSON & JOHNSON SURGICAL VISION, INC.
19071519 MEDICAL DEVICE Non-Final OA OLYMPUS MEDICAL SYSTEMS CORP.
18215975 DEPLOYMENT CONSTRAINING SHEATH THAT ENABLES STAGED DEPLOYMENT BY DEVICE SECTION Final Rejection W. L. Gore & Associates, Inc.
19191127 ANCHOR AND ANCHORING DEVICE Non-Final OA Micro-Tech (Nanjing) Co., Ltd.
18655945 ELECTROMAGNETIC SYSTEM FOR RAPID CANNULATION OF FENESTRATED ENDOVASCULAR GRAFTS Final Rejection University of Pittsburgh - Of the Commonwealth System of Higher Education
18884228 Cardiac Valve Loading Devices and Systems Final Rejection Cephea Valve Technologies, Inc.
18561425 System and Methods for Minimally Invasive Removal of Implanted Devices Non-Final OA NEURONOFF, INC.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month